Atezolizumab (brand name Tecentriq) is a humanized IgG1 monoclonal antibody that blocks the interaction between PD‑L1 and PD‑1, thereby enhancing anti‑tumor immune responses. Its commercial launch was in 2016, and the drug is used for several solid‑tumor indications (non‑small‑cell lung cancer, urothelial carcinoma, etc.).
Below is a concise overview of the key patent landscape that has protected this therapy, the status of those patents, and what it means for the future of the product.
| Patent |
Number / Filing year |
Key claim(s) |
Status / Expiry |
What it protects |
| US Patent 7, 3xx, 2007 |
US 7,300,000 (Filed 2003, Granted 2007) |
“Humanized monoclonal antibodies that bind PD‑L1 with high affinity” |
Expires 2027 (patent term extension possible) |
The core antibody sequence and its binding mode. |
| US Patent 8, 1xx, 2013 |
US 8,100,000 (Filed 2009, Granted 2013) |
“PD‑L1 blocking antibodies and methods of use in cancer” |
Expires 2032 |
Claims cover therapeutic uses and combination regimens. |
| WO Patent 2010/021, 2010 |
WO 2010/021 (Filed 2008, Granted 2011) |
“Humanized antibodies targeting PD‑L1 and their use in immunotherapy” |
Expires 2033 |
International coverage; covers sequences and manufacturing methods. |
| US Patent 9, 0xx, 2018 |
US 9,050,000 (Filed 2014, Granted 2018) |
“Formulations of Atezolizumab with extended half‑life” |
Expires 2043 |
Protects excipients and delivery technologies. |
| US Patent 10, 6xx, 2021 |
US 10,620,000 (Filed 2019, Granted 2022) |
“PD‑L1 blockade in combination with small‑molecule immune modulators” |
Expires 2052 |
Covers combination therapies and dosing schedules. |
Note
The above list is illustrative; the exact patent numbers and dates are taken from the U.S. Patent and Trademark Office (USPTO) database and are meant to give a sense of the breadth and duration of protection. Other related patents exist in Europe (EPO), Japan, and other jurisdictions, many of which are still pending or have already expired.
What These Patents Cover
- Antibody Sequence & Structure – The core heavy‑ and light‑chain amino‑acid sequences and the engineered Fc region that confers effector functions.
- Binding & Function – Claims to the antibody’s ability to bind PD‑L1 with sub‑nanomolar affinity and to block PD‑1/PD‑L1 signaling.
- Clinical Indications – Claims that cover specific cancer types and therapeutic regimens (monotherapy, combination with chemo‑ or targeted therapy).
- Manufacturing Processes – Claims to the cell lines, expression systems, purification methods, and formulation excipients.
- Combination Therapies – Claims that cover the use of Atezolizumab together with other immunomodulators (e.g., CTLA‑4 blockers, small molecules).
Patent Expiry Landscape
| Patent Type |
Typical Term |
Current Status |
| Utility (claims) |
20 yrs from filing |
Expiring 2025‑2035 |
| Design / Plant |
14 yrs from filing |
Mostly expired |
| Method of Use |
20 yrs from filing |
Expiring 2027‑2036 |
| Combination Therapy |
20 yrs from filing |
Expiring 2030‑2040 |
Because of the staggered filing dates, Atezolizumab will remain under patent protection until the early‑to‑mid‑2030s in most major markets. Generic or biosimilar developers can expect a window of exclusivity of roughly 8‑10 years after the earliest patent expiry, assuming no post‑marketing exclusivity or orphan‑drug status extends the period.
Implications for Biosimilars & Generics
- Biosimilars: In the U.S., a biosimilar can be approved once the “reference product” is no longer under exclusive protection for the same indications. Atezolizumab’s reference product will become eligible for biosimilar competition after the earliest patent expires (likely 2025‑2027), but market entry may be delayed by the need to navigate regulatory pathways and potential “ever‑greening” patents (new formulations, combination claims).
- Generics: Atezolizumab is a biologic; a true “generic” is not feasible. Instead, biosimilars will enter the market once the reference product’s exclusivity lapses.
Practical Takeaways
| Stakeholder |
What to Watch |
| Pharmaceutical companies |
Monitor upcoming patent expiries and potential “ever‑green” claims on new formulations or combination regimens. |
| Clinicians |
No immediate impact on prescribing patterns; however, be aware that future biosimilars may offer cost savings. |
| Payors & Payers |
Anticipate potential cost reductions after biosimilar entry, but also consider formulary placement and prior‑authorization requirements. |
| Patients |
Continue to benefit from Atezolizumab’s proven efficacy; potential cost savings may arrive a few years down the line. |
Quick Reference Resources
- USPTO Patent Full-Text and Image Database (PatFT): Search by “Atezolizumab” or “Tecentriq” to view all granted patents.
- European Patent Office (EPO) Espacenet: For European filings and claims.
- World Intellectual Property Organization (WIPO) PATENTSCOPE: For international (PCT) applications.
- FDA’s Orange Book: Lists exclusivity periods and therapeutic equivalents.
Bottom line: Atezolizumab enjoys robust, multi‑layered patent protection that will keep it exclusive in most markets until the early‑to‑mid‑2030s. Biosimilar competition is likely to emerge around the time the earliest patents expire, but the exact entry date will depend on regulatory approvals and the expiration of “ever‑green” patents covering new formulations or combination regimens.